4.8 Article

High flavivirus structural plasticity demonstrated by a non-spherical morphological variant

Journal

NATURE COMMUNICATIONS
Volume 11, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-020-16925-y

Keywords

-

Funding

  1. National Research Foundation Investigatorship award [NRF-NRFI2016-01]
  2. National Research Foundation competitive Research Project [NRF2016NRF-CRP001-063]
  3. Duke-NUS Signature Research Programme - Ministry of Health, Singapore
  4. Public Health Service grants from the National Institutes of Health, USA [GM122979, GM127365]

Ask authors/readers for more resources

Previous flavivirus (dengue and Zika viruses) studies showed largely spherical particles either with smooth or bumpy surfaces. Here, we demonstrate flavivirus particles have high structural plasticity by the induction of a non-spherical morphology at elevated temperatures: the club-shaped particle (clubSP), which contains a cylindrical tail and a disc-like head. Complex formation of DENV and ZIKV with Fab C10 stabilize the viruses allowing cryoEM structural determination to similar to 10 angstrom resolution. The caterpillar-shaped (catSP) Fab C10:ZIKV complex shows Fabs locking the E protein raft structure containing three E dimers. However, compared to the original spherical structure, the rafts have rotated relative to each other. The helical tail structure of Fab C10:DENV3 clubSP showed although the Fab locked an E protein dimer, the dimers have shifted laterally. Morphological diversity, including clubSP and the previously identified bumpy and smooth-surfaced spherical particles, may help flavivirus survival and immune evasion.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, Jiri Zahradnik, Piyada Supasa, Chang Liu, Helen M. E. Duyvesteyn, Helen M. Ginn, Alexander J. Mentzer, Aekkachai Tuekprakhon, Rungtiwa Nutalai, Beibei Wang, Aiste Dijokaite, Suman Khan, Ori Avinoam, Mohammad Bahar, Donal Skelly, Sandra Adele, Sile Ann Johnson, Ali Amini, Thomas G. Ritter, Chris Mason, Christina Dold, Daniel Pan, Sara Assadi, Adam Bellass, Nicola Omo-Dare, David Koeckerling, Amy Flaxman, Daniel Jenkin, Parvinder K. Aley, Merryn Voysey, Sue Ann Costa Clemens, Felipe Gomes Naveca, Valdinete Nascimento, Fernanda Nascimento, Cristiano Fernandes da Costa, Paola Cristina Resende, Alex Pauvolid-Correa, Marilda M. Siqueira, Vicky Baillie, Natali Serafin, Gaurav Kwatra, Kelly Da Silva, Shabir A. Madhi, Marta C. Nunes, Tariq Malik, Peter J. M. Openshaw, J. Kenneth Baillie, Malcolm G. Semple, Alain R. Townsend, Kuan-Ying A. Huang, Tiong Kit Tan, Miles W. Carroll, Paul Klenerman, Eleanor Barnes, Susanna J. Dunachie, Bede Constantinides, Hermione Webster, Derrick Crook, Andrew J. Pollard, Teresa Lambe, Neil G. Paterson, Mark A. Williams, David R. Hall, Elizabeth E. Fry, Juthathip Mongkolsapaya, Jingshan Ren, Gideon Schreiber, David Stuart, Gavin R. Screaton

Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article Microbiology

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants

Chang Liu, Daming Zhou, Rungtiwa Nutalai, Helen M. E. Duyvesteyn, Aekkachai Tuekprakhon, Helen M. Ginn, Wanwisa Dejnirattisai, Piyada Supasa, Alexander J. Mentzer, Beibei Wang, James Brett Case, Yuguang Zhao, Donal T. Skelly, Rita E. Chen, Sile Ann Johnson, Thomas G. Ritter, Chris Mason, Tariq Malik, Nigel Temperton, Neil G. Paterson, Mark A. Williams, David R. Hall, Daniel K. Clare, Andrew Howe, Philip J. R. Goulder, Elizabeth E. Fry, Michael S. Diamond, Juthathip Mongkolsapaya, Jingshan Ren, David Stuart, Gavin R. Screaton

Summary: This study investigated several variants of SARS-CoV-2 and found that the Beta variant has the largest antigenic difference compared to other variants, such as Delta, and is poorly neutralized by serum from early pandemic and Delta viruses. The study also revealed that certain antibodies can recognize conserved neutralizing epitopes, while others target specific mutated residues in the Beta variant.

CELL HOST & MICROBE (2022)

Letter Medicine, General & Internal

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Wanwisa Dejnirattisai, Robert H. Shaw, Piyada Supasa, Chang Liu, Arabella S. V. Stuart, Andrew J. Pollard, Xinxue Liu, Teresa Lambe, Derrick Crook, Dave I. Stuart, Juthathip Mongkolsapaya, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape, Gavin R. Screaton

LANCET (2022)

Article Medicine, General & Internal

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens, Lily Weckx, Ralf Clemens, Ana Verena Almeida Mendes, Alessandra Ramos Souza, Mariana B. Silveira, Suzete Nascimento Farias da Guarda, Maristela Miyamoto de Nobrega, Maria Isabel de Moraes Pinto, Isabela G. S. Gonzalez, Natalia Salvador, Marilia Miranda Franco, Renata Navis de Avila Mendonca, Isabelle Silva Queiroz Oliveira, Bruno Solano de Freitas Souza, Mayara Fraga, Parvinder Aley, Sagida Bibi, Liberty Cantrell, Wanwisa Dejnirattisai, Xinxue Liu, Juthathip Mongkolsapaya, Piyada Supasa, Gavin R. Screaton, Teresa Lambe, Merryn Voysey, Andrew J. Pollard

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart, Robert H. Shaw, Xinxue Liu, Melanie Greenland, Parvinder K. Aley, Nick J. Andrews, J. C. Cameron, Sue Charlton, Elizabeth A. Clutterbuck, Andrea M. Collins, Tom Darton, Tanya Dinesh, Christopher J. A. Duncan, Anna England, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Anna L. Goodman, Christopher A. Green, Bassam Hallis, Paul T. Heath, Helen Hill, Bryn M. Horsington, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Patrick J. Lillie, Yama F. Mujadidi, Ruth Payne, Emma L. Plested, Samuel Provstgaard-Morys, Maheshi N. Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Gavin R. Screaton, Nisha Singh, David P. J. Turner, Paul J. Turner, Iason Vichos, Rachel White, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

Article Immunology

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Yanchun Peng, Suet Ling Felce, Danning Dong, Frank Penkava, Alexander J. Mentzer, Xuan Yao, Guihai Liu, Zixi Yin, Ji-Li Chen, Yongxu Lu, Dannielle Wellington, Peter A. C. Wing, Delaney C. C. Dominey-Foy, Chen Jin, Wenbo Wang, Megat Abd Hamid, Ricardo A. Fernandes, Beibei Wang, Anastasia Fries, Xiaodong Zhuang, Neil Ashley, Timothy Rostron, Craig Waugh, Paul Sopp, Philip Hublitz, Ryan Beveridge, Tiong Kit Tan, Christina Dold, Andrew J. Kwok, Charlotte Rich-Griffin, Wanwisa Dejnirattisa, Chang Liu, Prathiba Kurupati, Isar Nassiri, Robert A. Watson, Orion Tong, Chelsea A. Taylor, Piyush Kumar Sharma, Bo Sun, Fabiola Curion, Santiago Revale, Lucy C. Garner, Kathrin Jansen, Ricardo C. Ferreira, Moustafa Attar, Jeremy W. Fry, Rebecca A. Russell, Hans J. Stauss, William James, Alain Townsend, Ling-Pei Ho, Paul Klenerman, Juthathip Mongkolsapaya, Gavin R. Screaton, Calliope Dendrou, Stephen N. Sansom, Rachael Bashford-Rogers, Benny Chain, Geoffrey L. Smith, Jane A. McKeating, Benjamin P. Fairfax, Paul Bowness, Andrew J. McMichael, Graham Ogg, Julian C. Knight, Tao Dong

Summary: Specific CD8(+) T cell responses targeting NP105-113-B*07:02 are associated with mild COVID-19 disease and high antiviral efficacy, providing potential targets for T cell vaccine design. These T cell responses show long-lasting preservation of antiviral functionality post-infection.

NATURE IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Jia Wei, Koen B. Pouwels, Nicole Stoesser, Philippa C. Matthews, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John Bell, John N. Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E. Yvonne Jones, David Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre

Summary: This study investigated the antibody responses and protection following the second doses of ChAdOx1 or BNT162b2 vaccines against SARS-CoV-2 in the general population of the United Kingdom. The results showed significant boosting of anti-spike IgG antibody levels after the second doses of both vaccines, with BNT162b2 generating higher peak levels than ChAdOX1. Older individuals, males, and prior infection influenced the antibody levels. The levels of anti-spike IgG were associated with protection from infection after vaccination, and previous infection enhanced antibody peak levels and half-life. At least 67% protection against infection is estimated to last for 2-3 months after two ChAdOx1 doses, 5-8 months after two BNT162b2 doses in uninfected individuals, and 1-2 years after natural infection in unvaccinated individuals. A third booster dose may be necessary, prioritizing ChAdOx1 recipients and those more clinically vulnerable.

NATURE MEDICINE (2022)

Article Medicine, Research & Experimental

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ane Ogbe, Matthew Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari, Anna Bara, Samantha Broadhead, Anthony Brown, Helen Brown, Federica Cappuccini, Paola Cinardo, Wanwisa Dejnirattisai, Katie J. Ewer, Henry Fok, Pedro M. Folegatti, Jamie Fowler, Leila Godfrey, Anna L. Goodman, Bethany Jackson, Daniel Jenkin, Mathew Jones, Stephanie Longet, Rebecca A. Makinson, Natalie G. Marchevsky, Moncy Mathew, Andrea Mazzella, Yama F. Mujadidi, Lucia Parolini, Claire Petersen, Emma Plested, Katrina M. Pollock, Thurkka Rajeswaran, Maheshi N. Ramasamy, Sarah Rhead, Hannah Robinson, Nicola Robinson, Helen Sanders, Sonia Serrano, Tom Tipton, Anele Waters, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Gavin R. Screaton, Alan Winston, Adrian V. S. Hill, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Sarah Fidler, Julie Fox, Teresa Lambe, John Frater

Summary: The duration of protection from SARS-CoV-2 infection after vaccination in people living with HIV (PWH) is unclear. A substudy of the COV002 trial was conducted on 54 HIV-positive male participants who received two doses of ChAdOx1 nCoV-19 (AZD1222). The study showed that immune responses were greater than baseline but declined after 6 months. However, there was no significant difference compared with HIV-uninfected individuals who received the same vaccine. Responses to the variants of concern were detectable but lower. Cross-reactive T cell responses to SARS-CoV-2 spike protein were associated with stronger post-vaccine immunity.

JCI INSIGHT (2022)

Article Biochemistry & Molecular Biology

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Rungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, Helen M. Ginn, Piyada Supasa, Chang Liu, Jiandong Huo, Alexander J. Mentzer, Helen M. E. Duyvesteyn, Aiste Dijokaite-Guraliuc, Donal Skelly, Thomas G. Ritter, Ali Amini, Sagida Bibi, Sandra Adele, Sile Ann Johnson, Bede Constantinides, Hermione Webster, Nigel Temperton, Paul Klenerman, Eleanor Barnes, Susanna J. Dunachie, Derrick Crook, Andrew J. Pollard, Teresa Lambe, Philip Goulder, Neil G. Paterson, Mark A. Williams, David R. Hall, Juthathip Mongkolsapaya, Elizabeth E. Fry, Wanwisa Dejnirattisai, Jingshan Ren, David Stuart, Gavin R. Screaton

Summary: This study compares the neutralization of Omicron variants of SARS-CoV-2 and finds that differences in neutralization mostly arise from variations in residues bordering the ACE2 binding site. Analysis of monoclonal antibodies isolated from vaccinated individuals shows that they can effectively neutralize early pandemic strains and exhibit broad reactivity with variants.
Article Biochemistry & Molecular Biology

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

David J. Ahern, Zhichao Ai, Mark Ainsworth, Chris Allan, Alice Allcock, Brian Angus, M. Azim Ansari, Carolina Arancibia-Carcamo, Dominik Aschenbrenner, Moustafa Attar, J. Kenneth Baillie, Eleanor Barnes, Rachael Bashford-Rogers, Archana Bashyal, Sally Beer, Georgina Berridge, Amy Beveridge, Sagida Bibi, Tihana Bicanic, Luke Blackwell, Paul Bowness, Andrew Brent, Andrew Brown, John Broxholme, David Buck, Katie L. Burnham, Helen Byrne, Susana Camara, Ivan Candido Ferreira, Philip Charles, Wentao Chen, Yi-Ling Chen, Amanda Chong, Elizabeth A. Clutterbuck, Mark Coles, Christopher P. Conlon, Richard Cornall, Adam P. Cribbs, Fabiola Curion, Emma E. Davenport, Neil Davidson, Simon Davis, Calliope A. Dendrou, Julie Dequaire, Lea Dib, James Docker, Christina Dold, Tao Dong, Damien Downes, Hal Drakesmith, Susanna J. Dunachie, David A. Duncan, Chris Eijsbouts, Robert Esnouf, Alexis Espinosa, Rachel Etherington, Benjamin Fairfax, Rory Fairhead, Hai Fang, Shayan Fassih, Sally Felle, Maria Fernandez Mendoza, Ricardo Ferreira, Roman Fischer, Thomas Foord, Aden Forrow, John Frater, Anastasia Fries, Veronica Gallardo Sanchez, Lucy C. Garner, Clementine Geeves, Dominique Georgiou, Leila Godfrey, Tanya Golubchik, Maria Gomez Vazquez, Angie Green, Hong Harper, Heather A. Harrington, Raphael Heilig, Svenja Hester, Jennifer Hill, Charles Hinds, Clare Hird, Ling-Pei Ho, Renee Hoekzema, Benjamin Hollis, Jim Hughes, Paula Hutton, Matthew A. Jackson-Wood, Ashwin Jainarayanan, Anna James-Bott, Kathrin Jansen, Katie Jeffery, Elizabeth Jones, Luke Jostins, Georgina Kerr, David Kim, Paul Klenerman, Julian C. Knight, Vinod Kumar, Piyush Kumar Sharma, Prathiba Kurupati, Andrew Kwok, Angela Lee, Aline Linder, Teresa Lockett, Lorne Lonie, Maria Lopopolo, Martyna Lukoseviciute, Jian Luo, Spyridoula Marinou, Brian Marsden, Jose Martinez, Philippa C. Matthews, Michalina Mazurczyk, Simon McGowan, Stuart McKechnie, Adam Mead, Alexander J. Mentzer, Yuxin Mi, Claudia Monaco, Ruddy Montadon, Giorgio Napolitani, Isar Nassiri, Alex Novak, Darragh P. O'Brien, Daniel O'Connor, Denise O'Donnell, Graham Ogg, Lauren Overend, Inhye Park, Ian Pavord, Yanchun Peng, Frank Penkava, Mariana Pereira Pinho, Elena Perez, Andrew J. Pollard, Fiona Powrie, Bethan Psaila, T. Phuong Quan, Emmanouela Repapi, Santiago Revale, Laura Silva-Reyes, Jean-Baptiste Richard, Charlotte Rich-Griffin, Thomas Ritter, Christine S. Rollier, Matthew Rowland, Fabian Ruehle, Mariolina Salio, Stephen Nicholas Sansom, Raphael Sanches Peres, Alberto Santos Delgado, Tatjana Sauka-Spengler, Ron Schwessinger, Giuseppe Scozzafava, Gavin Screaton, Anna Seigal, Malcolm G. Semple, Martin Sergeant, Christina Simoglou Karali, David Sims, Donal Skelly, Hubert Slawinski, Alberto Sobrinodiaz, Nikolaos Sousos, Lizzie Stafford, Lisa Stockdale, Marie Strickland, Otto Sumray, Bo Sun, Chelsea Taylor, Stephen Taylor, Adan Taylor, Supat Thongjuea, Hannah Thraves, John A. Todd, Adriana Tomic, Orion Tong, Amy Trebes, Dominik Trzupek, Felicia Anna Tucci, Lance Turtle, Irina Udalova, Holm Uhlig, Erinke van Grinsven, Iolanda Vendrell, Marije Verheul, Alexandru Voda, Guanlin Wang, Lihui Wang, Dapeng Wang, Peter Watkinson, Robert Watson, Michael Weinberger, Justin Whalley, Lorna Witty, Katherine Wray, Luzheng Xue, Hing Yuen Yeung, Zixi Yin, Rebecca K. Young, Jonathan Youngs, Ping Zhang, Yasemin-Xiomara Zurke

Summary: The study presents a comprehensive blood atlas for patients with varying severity of COVID-19, compared to influenza, sepsis patients, and healthy volunteers. The results identify immune signatures and correlates of host response, including cells, inflammatory mediators, immune repertoire, and metabolic and coagulation features. The study also reveals that persistent immune activation is a specific feature of COVID-19. Plasma proteomic analysis enables sub-phenotyping and prediction of severity and outcome. Integrative analyses show feature groupings linked with severity and specificity compared to influenza and sepsis.
Article Biochemistry & Molecular Biology

Charged Residue Implantation Improves the Affinity of a Cross-Reactive Dengue Virus Antibody

Huiling Wei, Jie Tan, Bingjie Zhou, Xiaotong Guan, Qiaoxian Zhong, Jiaqi Wang

Summary: This study demonstrated the utility of tweaking antibody-antigen charge complementarity for affinity maturation and emphasized the complexity of improving antibody affinity toward multiple antigens. By analyzing the structure of a specific antibody-antigen complex and designing mutations based on complementary charges, the researchers were able to enhance the affinity of the antibody towards different serotypes of dengue virus. The results showed that the mutations improved affinity through different mechanisms and had additive effects on affinity improvement.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Infectious Diseases

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial

Xinxue Liu, Alasdair P. S. Munro, Shuo Feng, Leila Janani, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L. Goodman, Christopher A. Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J. Llewelyn, Alastair C. McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F. Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R. Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R. Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C. Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S. Nguyen-Van-Tam, Victoria Cornelius, Matthew D. Snape, Saul N. Faust

Summary: The decay rates of humoral response differ between vaccines 84 days after a third dose of COVID-19 vaccine. The anti-spike IgG concentrations following BNT/BNT initial doses were similar to or higher than for a three-dose BNT schedule. Half dose BNT immune responses were similar to full dose responses.

JOURNAL OF INFECTION (2022)

Article Microbiology

Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages

Tessa Prince, Xiaofeng Dong, Rebekah Penrice-Randal, Nadine Randle, Catherine Hartley, Hannah Goldswain, Benjamin Jones, Malcolm G. Semple, J. Kenneth Baillie, Peter J. M. Openshaw, Lance Turtle, Grant L. Hughes, Enyia R. Anderson, Edward Patterson, Julian Druce, Gavin Screaton, Miles W. Carroll, James P. Stewart, Julian A. Hiscox

Summary: New variants of SARS-CoV-2 are continuously emerging. Understanding virus evolution and selection pressures requires considering population dynamics and new variants.

MSPHERE (2022)

Article Medicine, General & Internal

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Alexandra J. Spencer, Susan Morris, Marta Ulaszewska, Claire Powers, Reshma Kailath, Cameron Bissett, Adam Truby, Nazia Thakur, Joseph Newman, Elizabeth R. Allen, Indra Rudiansyah, Chang Liu, Wanwisa Dejnirattisai, Juthathip Mongkolsapaya, Hannah Davies, Francesca R. Donnellan, David Pulido, Thomas P. Peacock, Wendy S. Barclay, Helen Bright, Kuishu Ren, Gavin Screaton, Patrick McTamney, Dalan Bailey, Sarah C. Gilbert, Teresa Lambe

Summary: This study describes the generation and preclinical assessment of a vaccine targeting Beta VoC (B.1.351), which shows immunogenicity after a single dose and produces antibody responses to other variants as a booster, along with a strong T cell response.

EBIOMEDICINE (2022)

Article Chemistry, Physical

Glycine Substitution of Residues with Unfavored Dihedral Angles Improves Protein Thermostability

Zhili Lu, Qiaoxian Zhong, Jingxian Li, Bingjie Zhou, Yan-Ni Xing, Kaien Liu, Kexin Cao, Dongming Lan, Teng Zhou, Yonghua Wang, Jiaqi Wang

Summary: This study used computational approaches and mutagenesis strategies to enhance the stability of a diacylglycerol-specific lipase. Several mutations were found to significantly improve the thermostability and enzymatic activity of the enzyme. Structural analysis revealed how these mutations can release steric strain and increase stability. This suggests that substitution with glycine could be a promising strategy for improving protein thermostability.

CATALYSTS (2022)

No Data Available